C. Lamers

发表

Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.

M. Schubert-Zsilavecz, E. Proschak, D. Merk, 2015, Bioorganic & medicinal chemistry.

Revealing the macromolecular targets of complex natural products.

Petra Schneider, Gisbert Schneider, Daniel Reker, 2014, Nature chemistry.

Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.

D. Steinhilber, M. Schubert-Zsilavecz, Franca-Maria Klingler, 2012, Journal of medicinal chemistry.

Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition.

G. Schneider, O. Werz, M. Schubert-Zsilavecz, 2014, Bioorganic & medicinal chemistry letters.

Molecular tuning of farnesoid X receptor partial agonism

K. Saxena, H. Schwalbe, M. Schubert-Zsilavecz, 2019, Nature Communications.

Compstatins: the dawn of clinical C3-targeted complement inhibition.

John D Lambris, D. Ricklin, J. Lambris, 2022, Trends in pharmacological sciences.

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2012, Expert opinion on therapeutic patents.

SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.

M. Schubert-Zsilavecz, D. Merk, A. Kaiser, 2016, Future medicinal chemistry.

Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2013, Expert opinion on therapeutic patents.

Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012)

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2013, Expert opinion on therapeutic patents.

Design and synthesis of fused soluble epoxide hydrolase/peroxisome proliferator-activated receptor modulators

Sandra K. Wittmann, D. Steinhilber, M. Schubert-Zsilavecz, 2016 .

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

R. Rieben, C. Lamers, X. Kong, 2020, Nature Communications.

Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies

M. J. van den Bent, P. S. Sillevis Smitt, J. Gratama, 2002, Annals of Hematology.

Complement-regulatory biomaterial coatings: activity and selectivity profile of the factor H-binding peptide 5C6.

D. Ricklin, J. Lambris, S. Koutsogiannaki, 2022, Acta biomaterialia.

Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.

J. Goto, B. Stegmayr, C. Lamers, 2021, Journal of medicinal chemistry.

Overcoming the shortcomings of peptide-based therapeutics

C. Lamers, 2022, Future Drug Discovery.

The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology

D. Ricklin, C. Lamers, Carla Johanna Plüss, 2021, Frontiers in Immunology.

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).

G. Schneider, O. Werz, M. Schubert-Zsilavecz, 2014, Bioorganic & medicinal chemistry.

Macrocyclization strategies for cyclic peptides and peptidomimetics

C. Lamers, Clément Bechtler, 2021, RSC medicinal chemistry.

N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.

Sandra K. Wittmann, D. Steinhilber, B. Brüne, 2016, Journal of medicinal chemistry.

Nonacidic Farnesoid X Receptor Modulators.

Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk, 2017, Journal of medicinal chemistry.

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

D. Ricklin, J. Lambris, P. Gros, 2022, Nature Communications.

Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2014, Current topics in medicinal chemistry.

Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery

John D Lambris, D. Ricklin, J. Lambris, 2023, American journal of hematology.

SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.

O. Werz, M. Schubert-Zsilavecz, Isabella Ogorek, 2015, Bioorganic & medicinal chemistry letters.

Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.

M. Schubert-Zsilavecz, E. Proschak, C. Lamers, 2014, Bioorganic & medicinal chemistry letters.

Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.

G. Schneider, D. Steinhilber, M. Schubert-Zsilavecz, 2014, Journal of medicinal chemistry.

We are MedChem: The Frontiers in Medicinal Chemistry 2024.

C. Lamers, M. Gehringer, Felix Pape, 2024, ChemMedChem.